IONS ▲ +3.7% - Ionis Pharmaceuticals, Inc. $IONS Ionis announces positive topline results from Phase 3 FUSION study of ulefnersen marking significant milestone in advancing first potential disease modifying treatment for FUS-ALS Ionis Pharmaceuticals rallied 3.7% after announcing positive topline results from its Phase 3 FUSION study of ulefnersen for FUS-ALS, a rare form of amyotrophic lateral sclerosis. The positive data marks a key milestone toward potential regulatory approval of what could be the first disease-modifying treatment for this patient population, supporting the stock's advance. 22-SEP-2026 08:05 AM ET